Bristol-Myers Squibb (NYSE:BMY) Sees Rising Interest in Sotyktu Despite 3% Share Price Dip
Bristol-Myers Squibb (NYSE:BMY) recently announced positive topline results from its Phase 3 trials for Sotyktu, generating ...
Global Radiotherapy Market Expected To Reach $9.62 Billion By 2030 Realizing Growth Due To Technological Advancements - Financial News Media
The development of advanced radiotherapy technologies has, in turn, resulted in an increased complexity of operations. Also, a high level of accuracy is needed at every step of the process to achieve ...
Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements
The development of advanced radiotherapy technologies has, in turn, resulted in an increased complexity of operations. Also, a high level of accuracy is needed at every step of the process to achieve ...
CAR T-Cell Therapy Market Size To Reach 27.5 Billion by 2033 Owing to Rising Awareness and Favourable Reimbursement Policies Says Astute Analytica
The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, reflecting a robust CAGR of 26.2%.
Is Bristol-Myers Squibb (BMY) The Best Healthcare Dividend Stock to Invest in?
We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look ...
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Recent News: On March 20, CVS Health reported its board of directors has approved a quarterly dividend of 66.5 cents per share on the Common Stock of the Corporation. Edge Stock Ratings: 62.89 ...
Is Bristol-Myers Squibb (BMY) Among the Cheap Stocks to Buy According to Billionaires?
We recently published a list of the 15 Best and Cheap Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands ...
National Health Executive11d
Groundbreaking new cancer therapy approved
Final guidance published today recommends lisocabtagene maraleucel (also known as liso-cel or Breyanzi, made by Bristol Myers ...
Pharmaceutical Technology12d
EC approves Bristol Myers Squibb’s follicular lymphoma CAR T therapy
The EC has granted expanded approval to BMS' Breyanzi, to treat adults with relapsed or refractory follicular lymphoma (FL).
PMLive14d
Bristol Myers Squibb granted EC approval for Breyanzi in follicular lymphoma
Bristol Myers Squibb (BMS) has received approval from the European Commission (EC) for its CD19-directed CAR T cell therapy Breyanzi (lisocabtagene maraleucel) in follicular lymphoma (FL).
The Pharma Letter14d
EC expands use of CAR T cell therapy Breyanzi
The European Commission (EC) has granted approval to Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy from Bristol Myers Squibb (NYSE: BMY) ...
Pharmabiz14d
Bristol Myers Squibb gets European Commission approval to expand use of CAR T cell therapy, Breyanzi for relapsed or refractory follicular lymphoma
Bristol Myers Squibb announced that the European Commission (EC) has granted approval to Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, ...